Research summary ·
Short-chain enoyl-CoA hydratase deficiency: a systematic review of clinical spectrum, genotype-phenotype correlations and survival predictors.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review looked at a rare disease called ECHS1 deficiency. It is caused by changes in both copies of the ECHS1 gene. The disease affects how the body breaks down a substance called valine. The team searched PubMed and Scopus for past reports. They used only reports where a gene test confirmed the disease. Each report had to give data on single patients. They also looked at how long people lived and what was linked to death.
What they found
The review held data on 165 people. Dystonia was the most common sign. Delay in child development came next. Brain scans most often showed changes in the globus pallidus. A urine marker was the most frequent lab finding. People whose illness began as newborns had the worst survival. Their median survival was 28 months. Onset in newborns was the only factor that predicted death on its own.
What it means for patients
The authors say newborn onset is the strongest sign of a higher risk of death. They say this shows why an early gene test matters. They mean this for unexplained metabolic brain illness. This is brain illness with changes in the basal ganglia.
Why it is not certain yet
The disease is rare, so only 165 people were in the review. The data came from earlier published reports. The team checked study quality, but the abstract does not give those results. The abstract does not say how many people died. A review can only be as good as the studies in it.
Source
Short-chain enoyl-CoA hydratase deficiency: a systematic review of clinical spectrum, genotype-phenotype correlations and survival predictors.
PubMed · PMID 42825840We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Dystonia publications